TRDA
Entrada Therapeutics, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.88
P/S
20.90
EV/EBITDA
-3.26
DCF Value
$9.91
FCF Yield
-24.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
-54.4%
Operating Margin
-621.1%
Net Margin
-565.5%
ROE
-39.8%
ROA
-38.1%
ROIC
-44.2%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $1.3M | $-39.2M | $-0.95 |
| FY 2025 | $25.4M | $-143.8M | $-3.47 |
| Q3 2025 | $1.6M | $-44.1M | $-1.06 |
| Q2 2025 | $1.9M | $-43.1M | $-1.04 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
-0.15
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.